SOL stock
Price history
+38.16% over the period1 year: from €47.70 (November 17, 2025) to €65.90 (November 17, 2026), +38.16%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 17, 2026 | €65.90 |
| October 30, 2026 | €59.80 |
| September 30, 2026 | €56.50 |
| August 31, 2026 | €56.30 |
| July 31, 2026 | €56.90 |
| June 30, 2026 | €58.20 |
| May 29, 2026 | €56.50 |
| April 30, 2026 | €57.60 |
| March 31, 2026 | €58.90 |
| February 27, 2026 | €51.60 |
| January 30, 2026 | €45.40 |
| December 30, 2025 | €48.95 |
| November 28, 2025 | €49.85 |
| November 17, 2025 | €47.70 |
At a glance
The company
Produces and distributes technical and medical gases, healthcare services, and advanced biomedical solutions for industrial and healthcare sectors
Latest results
Quarter to June 30, 2026 · EPS €0.99
TickerLandia's take on SOL
- Pricier than usual relative to earnings: P/E on the latest fiscal year 36 vs a median of 19 over its last 10 fiscal years.
- Pricier than similar companies: trailing 12-month P/E 35 vs 27 (+28%) in a group of 9.
- Strong point: Market momentum (82/100 in its group). Weak point: Dividend (33/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−2.42% from the 52-week high
Analysts · 4 analysts
Average target€66.88+3.52% vs. price
Buy 4 · Hold 0 · Sell 0 · Strong buy
TickerLandia Fingerprint: SOL
Compared with similar companies: very strong momentum.
Financials and price compared with 59 companies in the specialty chemicals industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Pricehigh74
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 34.6 60 Forward P/E 28.5 83 EV/EBITDA 15.6 69 Price/book 5.05 82 Price/sales 3.19 77 Profitabilityaverage60
How much it earns on revenue and capital.
Metric Value Position in group Net margin 9.2% 57 ROE 15.6% 67 ROA 7.3% 74 Gross margin 26.2% 36 Operating margin 15.1% 65 Earnings stabilityhigh60
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 2.0% 55 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 65 Growthhigh66
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +8.18% 91 Revenue growth (year over year) +9.40% 53 Earnings growth (year over year) +8.40% 55 Financial strengthhigh65
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Interest coverage 11.4 70 Net debt/EBITDAcounts in reverse: lower means more financial strength 1.11 78 Current ratio 2.22 74 Debt/equitycounts in reverse: lower means more financial strength 0.71 38 Dividendlow33
How much it returns to shareholders, and for how long.
Metric Value Position in group Consecutive dividend years at least 28 years 78 Dividend yield 0.7% 6 Payout ratio 23.6% 16 Market momentumvery strong82
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) +25.85% 97 Relative strength (6 months) +5.59% 68 1-year return +35.43% 80 Distance from 200-day average +14.19% 82 Risklow35
How much the price swings.
Metric Value Position in group Volatility (60 days) 30.9% 64 Beta (1 year) 0.39 18 Maximum drawdown (12 months) 17.2% 22
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 18, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
SOL is pricier than in the past and pricier than similar companies
On the latest fiscal year's earnings (2025), SOL's P/E today is 35.8, above the median of its last 10 fiscal years (18.6; between 12.0 and 26.6 from 2016 to 2025). SOL's P/E (trailing 12 months): 34.6, +28% against the median of a group of 9 similar companies (27.1).
Compared with 9 similar companies
| Metric | SOL | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 34.6 | Middle | |
| Forward P/E | 28.5 | High | |
| Operating margin | 15.1% | High | |
| ROE | 15.6% | High | |
| Debt/equity | 0.71 | Middle |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: SOL. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
€962.69M
Latest quarter · Q2 2026
Net income
€89.87M
Latest quarter · Q2 2026
Quarterly net margin
9.3%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- €5.99B
- P/E
- 34.6
- EPS
- €1.91
- Volume
- 77.86K
- Daily trading
- €2.61M
- Dividend yield
- 0.70%
- Last ex-dividend on May 18, 2026
How SOL is changing
All resultsRevenue grew 13.1% a year on average over the last 5 years
Operating margin rose from 11.0% to 14.9%
Free cash flow equal to 61% of net income
Returns
SOL returns with dividends
€1,000 invested in SOL 5 years ago, on November 17, 2021, would be worth €3,200 today with dividends reinvested: +220.05% in total, +26.20% per year. On price alone it would be €3,030 (+202.99%).
| Period | SOL | FTSE MIB | €1,000 becomes |
|---|---|---|---|
| 1 month | +17.68% | +3.59% | €1,177 |
| 6 months | +9.31% | +3.52% | €1,093 |
| Year to date | +34.63% | +13.13% | €1,346 |
| 1 year | +39.21% | +16.17% | €1,392 |
| 3 years | +146.47% | +72.37% | €2,465 |
| 5 years | +220.05% | +82.73% | €3,200 |
| 10 years | +938.36% | +207.13% | €10,384 |
Over the last 6 months it has done better than 77% of the stocks in the Materials sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. FTSE MIB: price only. Calculate your investment
The chart in detail
SOL: technical analysis
SOL is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 2.3% below its all-time closing high (€66.10, November 16, 2026).
- Trend
- Upward
- RSI (14 sessions)
- 65
- Between 30 and 70
- vs 200-session average
- +14.19%
Support and resistance
Price areas where SOL has stopped several times in the last year. They describe the chart; they are not forecasts.
- No resistance above: the price is near the highs of the year
- Last price€64.60
- Support€63.80−1.24%2 touches, last on July 27, 2026
- Support€60.90−5.73%3 touches, last on July 7, 2026
- Support€59.30−8.20%3 touches, last on October 6, 2026
Volatility and risk
Over the last year it has moved little with the FTSE MIB.
- Beta (1 year) vs FTSE MIB
- 0.39
- Volatility (60 sessions, annualised)
- 30.9%
- Largest fall in the last year
- −17.19%
Close of November 17, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
SOL: seasonality
Average monthly price change over 29 years
Over the last 29 years, the strongest month for SOL has been March: +3.18% on average, positive in 17 years out of 28. The weakest has been September: −1.25% on average, positive in 10 years out of 29. November, the current month, has been positive in 14 years out of 28 (+0.16% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +1.45% | +3.35% | 17 of 28 |
| February | +2.20% | +1.25% | 15 of 28 |
| March | +3.18% | +2.17% | 17 of 28 |
| April | +2.60% | +3.05% | 19 of 28 |
| May | +2.73% | +2.56% | 17 of 28 |
| June | +0.16% | −0.82% | 13 of 28 |
| July | +1.33% | +1.63% | 15 of 28 |
| August | +0.20% | +0.93% | 15 of 29 |
| September | −1.25% | −1.24% | 10 of 29 |
| October | +0.06% | +1.49% | 17 of 29 |
| November | +0.16% | 0.00% | 14 of 28 |
| December | +0.26% | +0.28% | 15 of 28 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
SOL and its competitors
Its sales reach Italian and foreign markets, where it supplies gases, equipment and services to factories as well as to hospitals and care providers. Industrial offerings span oxygen, nitrogen, argon, hydrogen, carbon dioxide and liquefied natural gas, alongside high purity and electronics gases. The healthcare arm covers medical gases, respiratory and infusion therapies, hospital hygiene, telemedicine and digital services. Specialised units add CRYOLAB, which handles biological samples, DIATHEVA, which develops monoclonal antibodies and molecular kits, and PERSONAL GENOMICS for precision medicine.
- Headquarters
- Monza, Italy
- Employees
- 8,000
- Founded
- 1927
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| SOLSOL | $6.58B | 15.1% | 34.6 | +9.31% |
| Croda InternationalCRDA | $6.81B | 7.3% | 64.4 | +36.74% |
| IMCDIMCD | $6.83B | 8.1% | 27.1 | +9.61% |
| FUCHSFPE | $5.91B | 13.1% | 17.2 | +26.11% |
| ArkemaAKE | $4.94B | 4.6% | 234.8 | −7.82% |
| Wacker ChemieWCH | $4.41B | 5.1% | — | −19.15% |
Same industry or related industries, similar size. Compare SOL with its competitors · Full profile
